ofloxacin has been researched along with Ventilator-Associated Pneumonia in 5 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pharmacokinetics of levofloxacin and outcome of levofloxacin therapy in critically ill patients with ventilator-associated pneumonia (VAP) were assessed." | 7.74 | Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia. ( Benko, R; Doro, P; Gardi, J; Hajdu, E; Matuz, M; Molnar, A; Nagy, E; Peto, Z; Soos, G, 2007) |
| "The pharmacokinetics of levofloxacin and outcome of levofloxacin therapy in critically ill patients with ventilator-associated pneumonia (VAP) were assessed." | 3.74 | Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia. ( Benko, R; Doro, P; Gardi, J; Hajdu, E; Matuz, M; Molnar, A; Nagy, E; Peto, Z; Soos, G, 2007) |
| "Levofloxacin (200 mg/kg) was 73% effective, and ciprofloxacin (35 mg/kg) was ineffective in preventing death." | 1.39 | Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible Acinetobacter baumannii isolates from nosocomial pneumonia patients. ( Davies, TA; He, W; Lynch, AS; Queenan, AM, 2013) |
| "A 55 year-old male patient with chronic renal failure was hospitalized in intensive care unit following cardiopulmonary arrest." | 1.38 | [A case of ventilator-associated pneumonia due to Pantoea agglomerans]. ( Altın, N; Argun, C; Canbakan, B; Cesur, S; Koldaş, K; Kurşun, O; Sencan, I; Unal, N, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Queenan, AM | 1 |
| Davies, TA | 1 |
| He, W | 1 |
| Lynch, AS | 1 |
| Green, O | 1 |
| Murray, P | 1 |
| Gea-Banacloche, JC | 1 |
| Hibbard, ML | 1 |
| Kopelman, TR | 1 |
| O'Neill, PJ | 1 |
| Maly, TJ | 1 |
| Matthews, MR | 1 |
| Cox, JC | 1 |
| Vail, SJ | 1 |
| Quan, AN | 1 |
| Drachman, DA | 1 |
| Kurşun, O | 1 |
| Unal, N | 1 |
| Cesur, S | 1 |
| Altın, N | 1 |
| Canbakan, B | 1 |
| Argun, C | 1 |
| Koldaş, K | 1 |
| Sencan, I | 1 |
| Benko, R | 1 |
| Matuz, M | 1 |
| Doro, P | 1 |
| Peto, Z | 1 |
| Molnar, A | 1 |
| Hajdu, E | 1 |
| Nagy, E | 1 |
| Gardi, J | 1 |
| Soos, G | 1 |
5 other studies available for ofloxacin and Ventilator-Associated Pneumonia
| Article | Year |
|---|---|
Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible Acinetobacter baumannii isolates from nosocomial pneumonia patients.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Carbapenems; Ciprofloxacin; Doripenem; D | 2013 |
Sepsis caused by Elizabethkingia miricola successfully treated with tigecycline and levofloxacin.
Topics: Anti-Bacterial Agents; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Levofloxa | 2008 |
Empiric, broad-spectrum antibiotic therapy with an aggressive de-escalation strategy does not induce gram-negative pathogen resistance in ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; Bacterial Infections; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug | 2010 |
[A case of ventilator-associated pneumonia due to Pantoea agglomerans].
Topics: Anti-Bacterial Agents; Cefoperazone; Cross Infection; Drug Therapy, Combination; Enterobacteriaceae | 2012 |
Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia.
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Critical Illness; Female; Humans; Levofloxacin; | 2007 |